 
						
								R&D							
							
								Leveraging on in-house R&D platform,the Company maintains a pipeline of projects in various clinical stages,covering a wide range of fields of indication							
						
								Remain True to Our Original Aspiration –Innovation Driven							
							
								In the early 1990s,  research and development team was established to carry out innovative research and development
In 1996, we established production plants for API (rb-bFGF) and formulations
In 1998, the first rb-bFGF surgical product Beifuji launched in China
In 1999, the first rb-bFGF ophthalmic product Beifushu Eye Drops launched in China
						In 1996, we established production plants for API (rb-bFGF) and formulations
In 1998, the first rb-bFGF surgical product Beifuji launched in China
In 1999, the first rb-bFGF ophthalmic product Beifushu Eye Drops launched in China
 
								
										IN-HOUSE R&D PLATFORMS									
									
										Solid R&D of biologic APIs and drug products									
								
									
										Growth 
Factor
																Factor
										rb-bFGF/rh-bFGF and others for the treatment of ocular surface wounds, topical wounds, nerve injuries									
								
									
										Antibody									
									
																
										mAb, bsAb, sdAb, scFv, ADC/FDC, etc.									
								
									
										Drug Formulation									
									
																
										Successfully developed eyedrops, eye gel, spray, lyophilized powder, gel									
								
									
										Blow-Fill-Seal 
(BFS)
															(BFS)
										Producing preservative-free single-dose drugs in particular ocular drugs									
								
							R&D CAPABILITIES						
					
						
							RESEARCH/
INNOVATION CENTRES
															INNOVATION CENTRES
							· Provincial Enterprise Technology Centre
· Guangdong Provincial Cytokine Engineering Technology Research Centre
· Guangdong Provincial Ophthalmic Medicine Engineering Technology Research Centre
· Guangdong Province Aerosol Inhalation Formulation Engineering Technology Research Centre
· China Pharmaceutical University Excellent Engineering Master's Internship Base
· The teaching and practice base of South China University of Technology, Wenzhou Medical University and Zunyi Medical University
· National Postdoctoral Research Station
					· Guangdong Provincial Cytokine Engineering Technology Research Centre
· Guangdong Provincial Ophthalmic Medicine Engineering Technology Research Centre
· Guangdong Province Aerosol Inhalation Formulation Engineering Technology Research Centre
· China Pharmaceutical University Excellent Engineering Master's Internship Base
· The teaching and practice base of South China University of Technology, Wenzhou Medical University and Zunyi Medical University
· National Postdoctoral Research Station
						
							HONOURS & AWARDS						
						
										
							· Undertook National "Ninth Five-Year Plan" major scientific and technological research project
· Undertook National "Torch Plan" Project
· Undertook National "Major New Drug Creation" Project
· Owns 111 patents, including 81 invention patents, 15 utility patents, 15 design patent
· rb-bFGF eye drops was awarded one of the National Outstanding Innovation
· rb-bFGF gel was awarded one of the National Outstanding Innovation
· Honoured with the second prize of "National Scientific and Technology Progress Award" issued by the State Council in 2004 and 2018
					· Undertook National "Torch Plan" Project
· Undertook National "Major New Drug Creation" Project
· Owns 111 patents, including 81 invention patents, 15 utility patents, 15 design patent
· rb-bFGF eye drops was awarded one of the National Outstanding Innovation
· rb-bFGF gel was awarded one of the National Outstanding Innovation
· Honoured with the second prize of "National Scientific and Technology Progress Award" issued by the State Council in 2004 and 2018
								R&D STRATEGY							
							
								To the Future —  Broad Innovation Prospects							
							
								Continued product development,Improve drug discovery
Ophthalmology: fast-follower and to identify new generation of therapeutics
Oncology: to be global stakeholder
						Ophthalmology: fast-follower and to identify new generation of therapeutics
Oncology: to be global stakeholder
						
							Research Centre (PRC)						
						
															
							· Located in Zhuhai City, Guangdong Province
· Conduct translational research
· Undertake for NMPA registration of in-house and overseas projects
· Talent incubation: National Post-Doctoral Research Centre set up in Zhuhai
					· Conduct translational research
· Undertake for NMPA registration of in-house and overseas projects
· Talent incubation: National Post-Doctoral Research Centre set up in Zhuhai
						
							Research Centre (Abroad)						
						
														
							· Located in Boston (US), London (UK) and Singapore
· Led by Dr. XUE Qi, Chief Scientific Officer of Company
· Mainly focus on the research and development of new drugs in the field of ophthalmology and oncology
					· Led by Dr. XUE Qi, Chief Scientific Officer of Company
· Mainly focus on the research and development of new drugs in the field of ophthalmology and oncology
 
				 粤公网安备 44049102496184号
粤公网安备 44049102496184号